January 23, 2021 2:55 pm
Five men died in the fire that broke out in a five- storey building in the SII's Manjaripremises on Thursday.
January 23, 2021 7:25 am
“We were hoping that there was no loss of life. When we got an initial report that there has been no loss of life, we were relieved and hence I sent out a tweet,” Poonawalla said.
January 05, 2021 8:21 pm
Bharat Biotech managing director Dr Krishna Ella had strongly lashed out against those who had criticised the accelerated emergency use authorisation (EUA) that was accorded to Covaxin.
November 29, 2020 9:07 pm
The notice sent to SII alleged that the man suffered acute encephalopathy, damage or disease that affects the brain, following vaccination and all tests confirmed that the setback in his health was due to the test vaccine.
November 29, 2020 4:13 am
Will apply for emergency use in two weeks, says Serum Institute
November 28, 2020 11:43 pm
The Prime Minister interacted with top scientists at Serum Institute of India and sought to know the status of the trials.
November 24, 2020 8:57 am
Poonawalla told The Indian Express that “Forty million doses (of the vaccine candidate) have already been produced and definitely we should be able to produce another 60 million doses in a minimum of 45 to 60 days.”
November 20, 2020 12:19 pm
Coronavirus vaccine price: Covishield is the name in India of the Covid-19 vaccine candidate developed by the University of Oxford and AstraZeneca. Promising results about the effectiveness of the candidate in vulnerable age groups were published in The Lancet on Thursday.
November 12, 2020 11:10 am
At present, SII and ICMR are conducting Phase 2/3 clinical trials of Covidshield at 15 different centres, across the country. It has completed the enrollment of all 1,600 participants on October 31.
November 05, 2020 11:07 am
Adar Poonawalla, CEO of SII said preliminary results have shown that there are no immediate concerns pertaining to the Covishield vaccine. A total of 1600 people have been administered the first dose across 17 sites, and each participant is being followed up for six months to ensure safety of the vaccine.